Founded in 2021, Serna Bio is building the first map of the druggable transcriptome, opening up the universe of RNA biology to small molecule drug discovery. Most current therapeutics target known proteins that make up only 2% of the genome, while 70% of the genome encodes RNA. This represents a significant area of biology that is yet to be explored or targeted therapeutically.

The Serna Bio discovery platform generates a unique understanding of what features of small molecules alter RNA functions through a proprietary database of transcriptome wide, functional RNA structures and their small molecule RNA-binders. Using an AI-powered platform, we are developing a pipeline of first-in-class specific and drug-like small molecules for class specific and drug-like small molecules for classically undruggable proteins and lncRNA targets. We have contributed to seminal work with a recent publication with the NCI (https://onlinelibrary.wiley.com/doi/10.1002/anie.202211358).